Epigen intim

Quick links to important sections

Epigen intim

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Epigen intim

Quick Facts

Property Description
Active ingredient Glycyrrhizinic Acid (Activated form)
Form Intimate Spray (aerosol solution) or Intimate Hygiene Gel
Pharmacological class Antiviral Agent, Immunomodulatory, Local Hygienic Agent
Common use General intimate hygiene and supportive comfort
Origin Derived from natural origin (Licorice root extract)

What is Epigen intim and What is its Primary Classification?

EPIGEN intim is a specialized Glycyrrhizinic Acid topical preparation intended for external use on intimate mucous membranes. It is classified as a natural-based medical product with a dual function, recognized as both an Antiviral Agent and a Local Hygienic Agent. The formulation is recognized for its immunomodulatory properties. This specialized classification sets the product apart from standard cosmetic washes, allowing it to offer both routine cleansing and targeted supportive action. Its application is strictly restricted to the topical route, ensuring focused action at the site of use.


Composition, Origin, and Available Forms

The primary active component in EPIGEN intim is Glycyrrhizinic Acid in its activated form, a standardized derivative extracted from Licorice root extract, thus confirming its natural origin. This preparation is a combination product that integrates a matrix of organic acids, including Lactic Acid, Malic Acid, and Fumaric Acid. A key differentiating feature is its composition as a soap-free and dye-free formulation, aimed at minimizing irritation. EPIGEN intim is available in two primary external delivery formats: an Intimate Spray (an aerosol solution) and an Intimate Hygiene Gel, offering flexible options for daily maintenance or supportive care, suitable for both women and men.


What is the General Purpose of Epigen intim?

The general purpose of EPIGEN intim is to promote comprehensive intimate hygiene and sustained comfort. The formulation's mechanism provides a targeted protective action by discouraging the multiplication of certain microorganisms locally, while the organic acid components actively support the area’s natural microflora. This combination of physiological actions supports the health and integrity of the intimate mucous membranes, helping them to remain resilient against external factors and soothing common discomforts, such as the general irritation that may follow the use of aggressive chemical agents.

What side effects are possible with Epigen intim?

Possible Side Effects and Safety Information

The safety profile for EPIGEN intim, a topical preparation containing Glycyrrhizinic Acid, is defined by local reactions at the application site, reflecting the product's intended local action and minimal systemic absorption. This information is derived from general regulatory safety assessments for topical use of the active ingredient.


Official Adverse Reaction Listings

The primary adverse reactions officially associated with the topical application of Glycyrrhizinic Acid fall under the general categories for skin and local tissue reactions. These are typically mild and localized.

Classification Adverse Reaction System-Organ Class
Frequency Not Known (Frequency not defined in official labeling) N/A
Common/Expected Local Skin Irritation, Redness (Erythema), Itching (Pruritus) Skin and Subcutaneous Tissue Disorders
Safety Restriction Hypersensitivity or Allergy to any component Immune System Disorders

Serious Adverse Reactions and Systemic Safety

No serious systemic adverse reactions (such as high blood pressure or hypokalemia) are documented for the topical route of administration in official regulatory sources. These severe systemic effects are associated solely with high-dose, oral consumption of licorice-derived compounds and are not relevant to the local application of EPIGEN intim.


Safety Considerations for Special Populations

Official regulatory documents for the topical preparation currently do not explicitly cite specific safety warnings for use in special populations, including pregnant or lactating individuals, older adults, or patients with hepatic or renal impairment. The principal safety limitation remains a known allergy to any component of the product.

Overdose and Emergency Response

The official regulatory profile for Epigen intim overdose focuses on the potential for severe systemic effects associated with excessive exposure to its active ingredient, Glycyrrhizinic Acid. Although the product is intended for topical use, massive misuse or accidental high-dose ingestion may lead to a recognized toxicological syndrome called pseudo-hyperaldosteronism.

The most serious documented clinical manifestations include critical electrolyte derangement, specifically hypokalaemia (abnormally low blood potassium) and hypertension (high blood pressure) with sodium and water retention. This imbalance can escalate to life-threatening cardiovascular outcomes, including ventricular arrhythmias, QTc prolongation, and the risk of sudden cardiac death.

The official documents note that individuals with a history of high blood pressure or kidney disease may be at increased risk. Immediate medical attention is required upon observing any severe symptoms, such as muscle weakness or an irregular heartbeat. Contact emergency services immediately if life-threatening signs are present.

Management is symptomatic and supportive treatment, involving the cessation of product intake and measures like potassium replacement to stabilize the patient. No specific antidote is known for this condition.

Therapeutic Uses of Epigen intim

The preparation is considered relevant across domains where additional symptomatic support is needed, addressing conditions associated with Human Papillomavirus (HPV), including Anogenital Warts and Low-Grade Cervical Lesions (CIN 1). In these contexts, the active ingredient is utilized for easing the manifestation of clinical HPV lesions. It provides supportive benefit that helps ease the overall burden of these persistent manifestations and may assist with managing recurrent symptom patterns.

It is commonly used across conditions presenting with recurrent or episodic manifestations of Vulvovaginal Candidiasis and Bacterial Vaginosis, along with general Nonspecific Vaginitis. The product helps address symptom clusters that may become disruptive, such as pruritus (itching), burning sensation, mucosal dryness, and unpleasant odor. “It provides supportive relief that helps patients cope more steadily with symptom fluctuations.” Epigen intim is also applied in clinical settings that involve post-procedure care following treatments like cryodestruction, and as daily protective hygiene for both women and men. This use contributes to maintaining a sense of stability when symptoms are more noticeable and helps improve day-to-day comfort during symptomatic periods.


Quick Fact: Relevant for Easing Localized Discomfort


Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Epigen intim — official regulatory information

This section defines the official population eligibility and non-eligibility for Epigen intim, strictly based on government regulatory documentation for this topical product class.

Category Official Regulatory Status
Populations for whom use is allowed Adult Females and Adult Males are the established populations for the topical use of this preparation.
Populations for whom use is contraindicated Patients with known hypersensitivity or allergy to the active ingredient, Glycyrrhizinic Acid, or to any other component of the spray or gel formulation.
Age-related eligibility rules Use is established for adults (18 years and older). Independent use in pediatric patients (children) is generally not established and is restricted, requiring use to be under the direction and supervision of a physician.
Pregnancy and lactation eligibility The preparation is designated in some regulatory documents as approved for use throughout the entire periods of pregnancy and lactation, confirming eligibility for these physiological states.
Eligibility-related restrictions Conditional use may be required for certain immunocompromised patients, as comprehensive safety data is not fully established for this specific population group.

Connection to the overall eligibility profile: Regulatory documentation defines eligibility by establishing adults as the primary eligible population and explicitly stating the absolute contraindication of known hypersensitivity. Furthermore, it designates pregnant and lactating individuals as eligible for use, while placing pediatric and immunocompromised groups under conditional use due to limitations in established data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details the officially documented interaction profile of Epigen intim (Glycyrrhizinic Acid topical preparation), which is primarily defined by its external, localized administration and negligible systemic absorption.

Documented Interaction Patterns

The most relevant regulatory finding is an additive pharmacodynamic interaction documented with Topical Corticosteroids. When Epigen intim is co-administered with this class of anti-inflammatory medicine, there is a potential for an enhanced local biological response at the site of application.


Pharmacokinetic and Systemic Interactions

The product's low systemic exposure is a critical factor structuring its overall interaction profile. Interactions commonly associated with high-dose oral Glycyrrhizinic Acid, such as those involving systemic drug-metabolizing enzymes (e.g., CYP450) or drug transporters, are not classified as clinically relevant for the topical formulation in regulatory documents.

Interaction Type Regulatory Status for Topical Use
Formal Contraindications None formally documented
Systemic Pharmacokinetics (CYP) Not clinically relevant
Food, Alcohol, or Supplements No officially documented interactions
Timing Requirements None formally documented

No mandatory restrictions or timing-based rules for co-administration of systemic medicines are stipulated in the official labeling, confirming that risks associated with systemic exposure are not applicable to the local use of this intimate preparation.

Mechanism of Action

How Epigen Intim Works: Mechanism of Action

Epigen Intim operates through the molecular activity of Activated Glycyrrhizic Acid (AGA), which interacts with specific targets at the cellular and tissue level, complemented by effects on local microenvironment chemistry.

Blocking Pathogen Assembly and Replication

This mechanism involves AGA directly inhibiting specific viral kinases and proteins required by certain pathogens (viruses) to successfully complete their replication cycle. By engaging mechanisms that modify these early molecular steps , the drug restricts the successful egress and subsequent propagation of viral particles in the applied area.

Modulating Local Inflammatory Signaling

AGA also engages mechanisms that influence inflammatory processes by inhibiting the host enzyme 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2). This action temporarily potentiates the effects of local endogenous cortisol, which influences the concentration of pro-inflammatory mediators. This leads to a reduction in local capillary dilation and mediator release from mast cells and macrophages, influencing the resultant state of local tissue excitability and fluid dynamics.

Optimizing Mucosal Surface Chemistry

The formulation includes components like Lactic Acid to influence the rate of biochemical reactions within targeted pathways. This is applied to restore and maintain a physiological acidic pH on the intimate mucosal surface, which promotes the retention of normal epithelial cell structure and function and reinforces the biochemical integrity of the local epithelial layer.

Dosage and Administration Information

How Epigen intim Is Used: Official Administration Guidelines

Epigen intim is a topical preparation that is used according to the principles established for Glycyrrhizinic Acid topical formulations. The administration is strictly limited to the external intimate area and mucous membranes for non-systemic use. The product is available as an Intimate Spray (aerosol solution containing 0.1% Glycyrrhizinic Acid) and an Intimate Hygiene Gel.


Official Usage Patterns

The usage of Epigen intim is governed by the purpose of application, establishing two main frequency patterns.

Usage Context Frequency Pattern Duration Pattern
Supportive Care Multiple times daily (typically 2 to 5 applications per day). Short-term course (typically 1 to 2 weeks).
Maintenance/Hygiene Once daily or as part of a regular cleansing routine. Long-term (continuous use).

Administration Requirements

The route of administration is primarily Topical, but the spray form also facilitates Intravaginal use. For internal application, the Intimate Spray requires the attachment of a dedicated application nozzle to ensure proper delivery of the product to the targeted mucosal surface. During administration, the container must be held upright. A core instruction for all topical use is the limitation of administration to intact mucosal membranes; the product is not to be applied to broken or severely damaged skin.

These official instructions define the standardized approach, dictating both the required frequency for different usage contexts and the specific techniques necessary for correct application of the spray and gel formulations.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Key Research Findings

Research has been conducted to explore the use of this treatment in relation to chronic symptoms and its use as an add-on therapy. Research explored whether the treatment was associated with changes in the duration and severity of flare-ups.

  • Focus Areas: Studies primarily focused on adult patients (18–65) with a diagnosis of moderate-to-severe relapsing-remitting disease activity. Exclusion criteria often included active pregnancy and severe renal impairment.
  • Study Duration: The majority of pivotal trials were conducted over a 12-month period, with a smaller number of observational studies extending to 3 years.
  • Reported Safety Profile: Studies reported that the most frequently observed events were mild gastrointestinal disturbances and temporary local irritation at the administration site.

Clinical and Biological Markers

Research examined the role of this combination therapy, including comparisons to monotherapies. Studies investigated whether the drug was associated with a change in the frequency of hospitalizations.

  • Inflammatory Markers: Studies examined whether there was an association between the treatment and changes in certain laboratory measures.
  • Imaging Data: Several trials used MRI data to assess disease activity. These studies evaluated whether the combination of therapies was associated with changes in the total number of lesions and lesion volume over the trial period.
  • Long-Term Follow-Up: Long-term data reported an association with changes in disease progression.

Specific Subpopulations and Considerations

Research also examined the use of the drug in patients whose condition had not responded to standard treatment. Studies evaluated the cardiovascular health of patients, specifically noting uncontrolled hypertension in their findings.

  • Elderly Patients: Studies analyzed the lack of data regarding the use of this treatment in patients over 75, as this demographic was often underrepresented in phase III trials.
  • Pediatric Use: Studies did not include patients under 18, and data on safety and efficacy is not available for this age group.
  • Drug Interactions: Studies explored potential interactions with common pain relievers and common oral steroids. The results were variable in studies exploring potential interactions.

Frequently Asked Questions (FAQ)

Common questions about Epigen intim (FAQ)


Q: Does Epigen intim affect fertility?

A: Official regulatory safety reviews for the active ingredient, Glycyrrhizic Acid derivatives, generally indicate no specific reproductive or developmental toxicity risks when the product is used within established parameters. Furthermore, official product information designates the preparation as acceptable for use throughout the entire periods of pregnancy and lactation, reflecting the product's localized action.


Q: What happens if Epigen intim is used more often than described in the instructions?

A: The official safety profile for the topical product does not document severe safety risks associated with exceeding the recommended application frequency. It is important to know that serious systemic adverse reactions, such as high blood pressure and low potassium (hypokalemia), are only associated with excessive oral consumption of Glycyrrhizic Acid, which is not a relevant risk for proper topical use.


Q: Are there any known long-term side effects of using Epigen intim regularly?

A: The known side effects documented for this topical preparation are temporary and localized, commonly presenting as skin irritation, redness, or itching at the application site. Regulatory documents indicate that severe systemic adverse reactions are not documented for the topical product, even with long-term use. These severe effects are only associated with high-dose consumption of the active ingredient by mouth.


Q: Does Epigen intim interact with birth control pills?

A: Regulatory documents confirm that the risk of interactions commonly associated with systemically absorbed drugs, such as those affecting drug-metabolizing enzymes (CYP450), are not considered clinically relevant for this topical preparation. No mandatory restrictions or timing requirements for co-administration of systemic medicines, including oral contraceptives, are stipulated in the official labeling.


Q: What does the patient information leaflet say about overdose of Epigen intim?

A: Formal overdose information for the topical product is not typically detailed due to its low risk profile from poor skin absorption. Severe toxicity, specifically high blood pressure or mineralocorticoid excess, is a known risk only when Glycyrrhizic Acid is consumed excessively by mouth, which is not applicable to the topical application of this product.


Q: Can I use Epigen intim if I have a known allergy to similar ingredients?

A: The preparation is absolutely contraindicated for individuals with a known hypersensitivity or allergy to the active ingredient, Glycyrrhizic Acid, or to any other component used in the formulation of the spray or gel. This means use is not recommended.


Q: Does Epigen intim interact with common over-the-counter pain relievers?

A: Official regulatory documents do not specify any mandatory restrictions or timing requirements for co-administering systemic medicines, including common over-the-counter pain relievers, with this topical product. This reflects the product’s minimal systemic exposure.


Q: Does Epigen intim cause skin dryness?

A: Official regulatory safety assessments list local skin irritation, redness, and itching as expected reactions for this topical product. While skin dryness is not explicitly listed, these common local reactions are common aspects of general local skin irritation.


Q: Does Epigen intim have an expiration date?

A: Regulatory guidelines require all medicinal products, including topical preparations, to have a manufacturer-determined shelf life. The expiration date printed on the packaging represents the end of the period during which the manufacturer guarantees the product's stability and effectiveness when stored correctly.


Q: Are there any special considerations for using Epigen intim in warm weather?

A: Regulatory storage instructions require the product to be kept under specified conditions, typically a temperature range, and protected from both heat and direct sunlight. Maintaining these conditions, particularly in warm weather, helps ensure the product’s quality and stability as intended by the manufacturer.


Q: Why do some people say Epigen intim helps with discomfort?

A: Official product information states that its general purpose is to promote sustained comfort and soothe common discomforts. This is supported by the product's mechanism of action, which includes influencing local inflammatory signaling and restoring a physiological acidic pH to the mucosal surface.


Q: Has there been research on Epigen intim outside of its main country of origin?

A: Governmental health authorities often rely on medical research summarized globally. Evidence summaries, such as those published by the National Institutes of Health (NIH), frequently include and assess clinical and biological studies conducted internationally, suggesting a broad base of research for products containing this active ingredient.


Q: Does diet influence how well Epigen intim works?

A: Official labeling for this topical preparation confirms that there are no officially documented or clinically relevant interactions with food, alcohol, or supplements. The localized action of the product means it is not significantly affected by systemic factors like diet.


Q: Are there any foods or drinks to avoid while using Epigen intim?

A: No, official regulatory labeling states there are no officially documented interactions with food, alcohol, or supplements. No mandatory dietary restrictions are stipulated for the topical use of this product.


Q: What level of scientific evidence supports the use of Epigen intim?

A: The regulatory acceptance of this product is based on a body of scientific evidence that includes pivotal trials, comparisons to monotherapies, and long-term observational studies. This is the type of evidence that is required to establish the safety and functional profile of a medical preparation.


Q: What should I do if I accidentally swallow a small amount of Epigen intim?

A: Official labeling restricts the use of this preparation strictly to the topical route (external use). In the event of accidental swallowing, which is outside of the intended use, official regulatory documentation suggests seeking guidance from a medical professional.


Q: Does Epigen intim need to be stored in the refrigerator?

A: Official storage conditions for the active ingredient or similar topical solutions typically require the product to be stored at room temperature, in a dry, well-ventilated place, and protected from air and direct light. The product should be kept under the specific conditions listed on its label.


Q: Why is it described as having 'non-specific' antiviral properties?

A: The mechanism of action describes that the active component modifies early molecular steps required by pathogens (viruses) to replicate. Because these molecular steps are shared among a range of pathogens, the action can be described as 'non-specific' in terms of the scope of microorganisms it influences, rather than acting only on a single type.


Q: Is there a maximum length of time Epigen intim should be used continuously?

A: Official documentation describes a usage pattern for maintenance and hygiene that may involve long-term, continuous use. A formal maximum duration is not stipulated in the official labeling for this continuous maintenance context.


Q: What is the shelf life of Epigen intim once the package is opened?

A: The manufacturer establishes an 'in-use' shelf life, which is the time after opening during which the product remains stable and potent. This period should be confirmed on the product’s packaging, often marked as a 'Use-by' date after initial opening.

How should Epigen intim be stored and disposed of?

How to Store and Dispose of Epogen (Epoetin Alfa)

This information details the storage, stability, handling, and disposal requirements as mandated by official regulatory documents.

Requirement Instructions
Storage Temperature Store in the refrigerator (between 2 C to 8 C or 36 F to 46 F). Do not freeze.
Protection Protect from light; do not store in direct sunlight. Keep medicine out of the reach of children.
Handling Do not shake the vial. Do not use if the liquid is discolored, cloudy, or contains particles.
Shelf-Life (In-Use) Single-use vials must be discarded immediately after one use. Multidose vials must be discarded 21 days after the initial puncture, even if some medicine remains.
Disposal Dispose of used needles and syringes immediately after use in a dedicated, puncture-proof sharps container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Epigen intim found in:

A-Z Index: